

# ASX Release

EMvision Medical Devices Ltd  
ACN 620 388 230  
Level 10, 12 Creek Street,  
Brisbane Qld 4000  
02 8667 5337  
contact@emvision.com.au

## EMVISION INVITED TO JOIN AUSTRALIAN STROKE ALLIANCE

### Highlights:

- *EMvision joins extensive partnership network, aimed at delivering disruptive technologies to transform pre-hospital stroke care for all Australians, especially within the first Golden Hour after stroke onset*
- *Australian Stroke Alliance includes prominent stroke clinicians, nurses, paramedics, health policy makers and experts in brain imaging and health economics across Australia*
- *The Alliance aims to address serious gaps in stroke treatment for rural, remote and urban settings including the development and roll out of novel candidate imaging tools, which includes EMvision's portable brain scanner currently in development*
- *EMvision is a commercial collaborator in the group's Medical Research Future Fund bid*

**EMvision Medical Devices Limited (ASX: EMV)** ("EMvision" or the "Company"), a medical device company focused on the development and commercialisation of medical imaging technology, is pleased to announce that the Company has been invited to join the newly created Australian Stroke Alliance as a key commercial collaborator.

Led by The Melbourne Brain Centre of the Royal Melbourne Hospital, the Australian Stroke Alliance brings together leaders across the healthcare sector to propose a transformative research program that aims to develop, test and implement breakthrough portable imaging technologies to transform access to early pre-hospital treatments.

Stroke is highly treatable but time critical, with the benefit of intravenous clot-busting (thrombolytic) therapy for acute ischemic stroke being maximal in the first 60 minutes (Golden Hour) after symptoms, and declining rapidly during the next 4.5 hours. Currently, access to early stroke diagnosis and treatment is poor, particularly in regional and remote Australia.

A significant obstacle to delivering these life-saving, clot-busting medications in the field is access to accurate brain imaging which is essential for stroke diagnosis. A cost-effective and portable brain-imaging tool would solve this serious unmet clinical need, enabling immediate treatment in the field and definitive patient triage.

Modest advances have allowed smaller (500kg) brain CT-scanners to be placed in ambulances in a few pilot centres around the world. However, scaled expansion of pre-hospital interventions has been limited by cost and the technical complexity of integrating large CT-scanners into vehicles to reach patients earlier.

EMvision is excited to participate in this program and investigate the Company's potentially lightweight, portable and cost-effective brain imaging technology, currently in development, at scale, in first responder scenarios.

The Alliance is led by Professor Geoffrey Donnan AO and Professor Stephen Davis AM. Professor Donnan said; “We look forward to validating EMvision’s imaging technology which we hope can be integrated into road mobility, enhancing clinical diagnosis and treatment of stroke in the golden hour, drastically improving patient outcomes.”

EMvision CEO, Dr Ron Weinberger said; “Being identified as a strategic industry partner validates the approach we are taking. This alliance, led by Professors Donnan and Davis at the Melbourne Brain Centre, has the potential to have a powerful impact on the health and wellbeing of Australians while reducing the national healthcare economic burden.”

The Australian Stroke Alliance has made an application for a competitive grant from the Medical Research Future Fund (MRFF) Frontier Health and Medical Research Program. The MRFF program operates under a 2-stage process:

- Stage 1 is an open competitive grant scheme, with researchers submitting proposals outlining their ideas and their associated merits. Successful applicants will receive approximately \$1 million to advance their projects over an initial 12 month period, ready to put forward for potential stage 2 investment.
- Stage 2 supports the best applicants from Stage 1 to realise new frontiers in health and medical research with up to 5 years of funding — ranging from \$10 million to \$20 million per year.

In the event the Australian Stroke Alliance’s MRFF bid is successful and progresses, it is expected that EMvision will provide in kind contributions and benefit from similar contributions made by other Australian Stroke Alliance program collaborators. EMvision’s participation is a non-binding initial framework without current financial impact, and would be subject to further agreements as the Australian Stroke Alliance progresses its various initiatives.

#### **[ENDS]**

For further information, media or investor enquires, please contact:

Michael Wills  
Investor & Media Relations  
+61 468 385 208  
michael@spring-communications.com.au

Scott Kirkland  
Executive Director  
+61 2 8667 5337  
skirkland@emvision.com.au

#### **About EMvision Medical Devices**

EMvision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of over 30 researchers is led by co-inventors Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging, along with Professor Stuart Crozier, who created technology central to most MRI machines manufactured since 1997.

#### **About The Australian Stroke Alliance**

The Alliance’s extensive collaborative networks bring together differentiated and complementary skills, including specialist stroke clinician-scientists, stroke nursing, paramedic leaders, air medicine, experts in diagnostic technology working with experts in engineering, artificial intelligence, brain imaging and health economics. Critically, the Alliance includes major national and state advocacy groups such as the Stroke Foundation and Neurosciences Victoria that plan to drive a Consumer Engagement Program.